You are here: Industry Insights > Market News > PM: Cambodians to receive AstraZeneca 3rd dose as 'booster'

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

PM: Cambodians to receive AstraZeneca 3rd dose as 'booster'

firstwordpharmaAugust 02, 2021

Tag: PM , AstraZeneca , COVID-19 Vaccines

Favorites

Cambodia prime minister Hun Sen said that the country will implement booster doses with COVID-19 vaccines, beginning with frontline workers, Khmer Times reported Sunday.

PM: Cambodians to receive AstraZeneca 3rd dose as 'booster'

Specifically, AstraZeneca's vaccine will be used as a booster for those previously immunised with shots from Sinopharm or Sinovac.

Meanwhile, people initially immunised with AstraZeneca's vaccine, will receive Sinopharm or Sinovac for their third dose.

Previous:Sputnik V vaccine production in India to go fully on stream in September: RDIF

Next:Research body recommends COVID-19 drug

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

PM: Cambodians to receive AstraZeneca 3rd dose as 'booster' | Pharmasources.com

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

PM: Cambodians to receive AstraZeneca 3rd dose as 'booster'

Related News

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

You may like